Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Porphyromonas gingivalis in Alzheimer's disease brains: Evidence for disease causation and treatment with small-molecule inhibitors.

Dominy SS, Lynch C, Ermini F, Benedyk M, Marczyk A, Konradi A, Nguyen M, Haditsch U, Raha D, Griffin C, Holsinger LJ, Arastu-Kapur S, Kaba S, Lee A, Ryder MI, Potempa B, Mydel P, Hellvard A, Adamowicz K, Hasturk H, Walker GD, Reynolds EC, Faull RLM, Curtis MA, Dragunow M, Potempa J.

Sci Adv. 2019 Jan 23;5(1):eaau3333. doi: 10.1126/sciadv.aau3333. eCollection 2019 Jan.

2.

Immunoproteasome functions explained by divergence in cleavage specificity and regulation.

Winter MB, La Greca F, Arastu-Kapur S, Caiazza F, Cimermancic P, Buchholz TJ, Anderl JL, Ravalin M, Bohn MF, Sali A, O'Donoghue AJ, Craik CS.

Elife. 2017 Nov 28;6. pii: e27364. doi: 10.7554/eLife.27364.

3.

Discovery of Highly Selective Inhibitors of the Immunoproteasome Low Molecular Mass Polypeptide 2 (LMP2) Subunit.

Johnson HWB, Anderl JL, Bradley EK, Bui J, Jones J, Arastu-Kapur S, Kelly LM, Lowe E, Moebius DC, Muchamuel T, Kirk C, Wang Z, McMinn D.

ACS Med Chem Lett. 2017 Mar 9;8(4):413-417. doi: 10.1021/acsmedchemlett.6b00496. eCollection 2017 Apr 13.

4.

Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay.

Lee SJ, Levitsky K, Parlati F, Bennett MK, Arastu-Kapur S, Kellerman L, Woo TF, Wong AF, Papadopoulos KP, Niesvizky R, Badros AZ, Vij R, Jagannath S, Siegel D, Wang M, Ahmann GJ, Kirk CJ.

Br J Haematol. 2016 Jun;173(6):884-95. doi: 10.1111/bjh.14014. Epub 2016 Apr 12.

5.

A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors.

Infante JR, Mendelson DS, Burris HA 3rd, Bendell JC, Tolcher AW, Gordon MS, Gillenwater HH, Arastu-Kapur S, Wong HL, Papadopoulos KP.

Invest New Drugs. 2016 Apr;34(2):216-24. doi: 10.1007/s10637-016-0327-x. Epub 2016 Feb 29.

PMID:
26924128
6.

Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death.

Mishima Y, Santo L, Eda H, Cirstea D, Nemani N, Yee AJ, O'Donnell E, Selig MK, Quayle SN, Arastu-Kapur S, Kirk C, Boise LH, Jones SS, Raje N.

Br J Haematol. 2015 May;169(3):423-34. doi: 10.1111/bjh.13315. Epub 2015 Feb 23.

PMID:
25709080
7.

A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity.

Eda H, Santo L, Cirstea DD, Yee AJ, Scullen TA, Nemani N, Mishima Y, Waterman PR, Arastu-Kapur S, Evans E, Singh J, Kirk CJ, Westlin WF, Raje NS.

Leukemia. 2014 Sep;28(9):1892-901. doi: 10.1038/leu.2014.69. Epub 2014 Feb 12.

PMID:
24518207
8.

Molecular mechanisms of bortezomib resistant adenocarcinoma cells.

Suzuki E, Demo S, Deu E, Keats J, Arastu-Kapur S, Bergsagel PL, Bennett MK, Kirk CJ.

PLoS One. 2011;6(12):e27996. doi: 10.1371/journal.pone.0027996. Epub 2011 Dec 22.

9.

Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events.

Arastu-Kapur S, Anderl JL, Kraus M, Parlati F, Shenk KD, Lee SJ, Muchamuel T, Bennett MK, Driessen C, Ball AJ, Kirk CJ.

Clin Cancer Res. 2011 May 1;17(9):2734-43. doi: 10.1158/1078-0432.CCR-10-1950. Epub 2011 Mar 1.

10.

An ab Initio structural model of a nucleoside permease predicts functionally important residues.

Valdés R, Arastu-Kapur S, Landfear SM, Shinde U.

J Biol Chem. 2009 Jul 10;284(28):19067-76. doi: 10.1074/jbc.M109.017947. Epub 2009 May 8.

11.

Identification of proteases that regulate erythrocyte rupture by the malaria parasite Plasmodium falciparum.

Arastu-Kapur S, Ponder EL, Fonović UP, Yeoh S, Yuan F, Fonović M, Grainger M, Phillips CI, Powers JC, Bogyo M.

Nat Chem Biol. 2008 Mar;4(3):203-13. doi: 10.1038/nchembio.70. Epub 2008 Feb 3.

PMID:
18246061
12.

Falstatin, a cysteine protease inhibitor of Plasmodium falciparum, facilitates erythrocyte invasion.

Pandey KC, Singh N, Arastu-Kapur S, Bogyo M, Rosenthal PJ.

PLoS Pathog. 2006 Nov;2(11):e117.

13.
14.

Novel aza peptide inhibitors and active-site probes of papain-family cysteine proteases.

Verhelst SH, Witte MD, Arastu-Kapur S, Fonovic M, Bogyo M.

Chembiochem. 2006 Jun;7(6):943-50.

PMID:
16607671
15.

Point mutations within the LdNT2 nucleoside transporter gene from Leishmania donovani confer drug resistance and transport deficiency.

Galazka J, Carter NS, Bekhouche S, Arastu-Kapur S, Ullman B.

Int J Biochem Cell Biol. 2006;38(7):1221-9. Epub 2006 Jan 24.

PMID:
16464630
16.

Second-site suppression of a nonfunctional mutation within the Leishmania donovani inosine-guanosine transporter.

Arastu-Kapur S, Arendt CS, Purnat T, Carter NS, Ullman B.

J Biol Chem. 2005 Jan 21;280(3):2213-9. Epub 2004 Oct 22.

17.

Functional analysis of an inosine-guanosine transporter from Leishmania donovani. The role of conserved residues, aspartate 389 and arginine 393.

Arastu-Kapur S, Ford E, Ullman B, Carter NS.

J Biol Chem. 2003 Aug 29;278(35):33327-33. Epub 2003 Jun 13.

Supplemental Content

Loading ...
Support Center